Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 9/20 | 0.62 |
| ▸ | VIPR1 | P32241 | 8/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 4/20 | 0.56 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | HRAS | P01112 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463855 | 0.94 | VIPR1 (0.66) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL30150683 | 0.91 | VIPR2 (0.59) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL30607476 | 0.91 | TFPI (0.67) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL31031604 | 0.90 | NPY4R (0.63) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL30719468 | 0.90 | TFPI (0.60) | VIPR2VIPR1TFPIHRASKRAS | |
| SCHEMBL29657455 | 0.90 | TFPI (0.61) | VIPR2VIPR1TFPIHRASKRAS | |
| SCHEMBL30176441 | 0.89 | TFPI (0.64) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL29634728 | 0.88 | TFPI (0.61) | VIPR2VIPR1TFPIKRAS | |
| SCHEMBL29519384 | 0.88 | TFPI (0.68) | VIPR2VIPR1TFPINPY1RNPY2R | |
| SCHEMBL31115950 | 0.88 | NPY4R (0.69) | NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12483047-B2 | Compositions and methods for treating and preventing macular degeneration | GENZYME CORPORATION (US) | 2025-11-25 | — | — | US | claimed |
| US-20220288232-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION | GENZYME CORPORATION | 2022-09-15 | — | — | US | claimed |
| EP-3600372-B1 | SYNTHEKINE COMPOSITIONS AND METHODS OF USE | UNIV LELAND STANFORD JUNIOR (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260109972-A1 | High-Throughput Discovery of Multi-Partite CRISPR-Based Editors | UNIV CALIFORNIA (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-12483047-B2 | Compositions and methods for treating and preventing macular degeneration | GENZYME CORPORATION (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250304702-A1 | WNT SIGNALING AGONIST MOLECULES | UNIVERSITY OF WASHINGTON | 2025-10-02 | — | — | US | disclosed |
| US-20250283088-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-09-11 | — | — | US | disclosed |
| EP-4599057-A1 | HIGH-THROUGHPUT DISCOVERY OF MULTI-PARTITE CRISPR-BASED EDITORS | The Regents of University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250250329-A1 | CYTOKINE ADAPTOR PROTEINS AND USES THEREOF | HOWARD HUGHES MEDICAL INSTITUTE | 2025-08-07 | — | — | US | disclosed |
| US-12344842-B2 | Compositions and methods for treating and preventing macular degeneration | GENZYME CORPORATION (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2023143619-A1 | NEUTRALIZING BLOCKING AGENT FOR BLOCKING INFECTION OF CELL BY VIRUS, PREPARATION METHOD THEREFOR AND USE THEREOF | 康码（上海）生物科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4217000-A1 | POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219564-A1 | WNT SIGNALING AGONIST MOLECULES | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230183359-A1 | WNT SIGNALING AGONIST MOLECULES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-3191526-B1 | WNT SIGNALING AGONIST MOLECULES | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-2968461-B1 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF | GENZYME CORP (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220288232-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION | GENZYME CORPORATION | 2022-09-15 | — | — | US | disclosed |
| WO-2022067178-A1 | POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220064262-A1 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF | GENZYME CORPORATION (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250329-A1 | CYTOKINE ADAPTOR PROTEINS AND USES THEREOF | IL6ST, TNFRSF1A, TRAF6 | VIPR2 2752/4885VIPR1 2299/4885TFPI 3299/4885 |
| US-20260109972-A1 | High-Throughput Discovery of Multi-Partite CRISPR-Based Editors | CPSF6, CPSF1, ZFR | VIPR2 3485/4885VIPR1 3693/4885TFPI 4385/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | VIPR2 2038/4885VIPR1 1401/4885TFPI 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.